Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00696891 | Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults | PHASE3 | COMPLETED | 380 | — | — | Jun 1, 1997 | - | Jun 13, 2008 | 3 | Belgium, Canada +1 |
| NCT00698906 | Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y | PHASE2 | COMPLETED | 160 | — | — | Jun 1, 1997 | - | Jun 17, 2008 | 1 | Austria |
| NCT00698555 | Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y | PHASE2 | COMPLETED | 163 | — | — | Mar 1, 1997 | - | Jun 17, 2008 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Group E | EXPERIMENTAL | - |
| Group F | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| HBV-MPL vaccine | BIOLOGICAL | 3-dose intramuscular injection |
| Engerix™-B | BIOLOGICAL | 3-dose intramuscular injection |
Inclusion Criteria: * Age: 50 to 70 years old. * Good physical condition as established by clinical examination and history taking at the time of entry. * Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. * Written info...